Akebia Therapeutics elects Ron Frieson as independent Class I director, effective Nov 1, 2021

Akebia Therapeutics, Inc.

Board expanded from 8 to 9 directors; Frieson's term expires at 2024 annual meeting.
Frieson determined independent per Nasdaq rules; no related-party transactions.
Entitled to annual cash retainer of $45,000, equity grants of 20,100 options and 13,700 RSUs.
Received initial director grant: option for 80,200 shares at $3.13 (Nov 1 closing price).
Standard indemnification agreement as per Company's non-employee director program.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ron Frieson

Class I director

AKBA · Akebia Therapeutics, Inc.

Effective: 2021-11-01
Filed: November 1, 2021, 7:59 PM ET

the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, increased the Board’s size from eight to nine directors and elected Ron Frieson as a Class I director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Frieson was elected as Class I director at Akebia Therapeutics, Inc..

Action: elected
Role: Class I director

Exact text from the filing

the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, increased the Board’s size from eight to nine directors and elected Ron Frieson as a Class I director.

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-315574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.